Case no | Age | FIGO stage | Residual disease | Chemotherapy | Chemosensitivity | Follow-up (months) | Survival Outcomes |
---|---|---|---|---|---|---|---|
1 | 57 | IIIC | R0 | Y | Y | 21 | Censored |
2 | 39 | IIIC | ≥1 cm | Y | Y | 20 | Alive |
3 | 77 | IC | R0 | NA | NA | NA | Censored |
4 | 27 | IIIC | ≥1 cm | Y | N | 18 | Died |
5 | 46 | IIIC | ≥1 cm | Y | N | 32 | Alive |
6 | 68 | IIIC | 0.1-1Â cm | Y | NA | 12 | Died |
7 | 49 | IIIC | 0.1-1Â cm | Y | N | 52 | Alive |
8 | 42 | IIIC | ≥1 cm | Y | N | 13 | Censored |
9 | 76 | IIIB | R0 | Y | Y | 22 | Alive |
10 | 57 | IIIC | 0.1-1Â cm | Y | Y | 20 | Alive |
11 | 54 | IIIC | 0.1-1Â cm | Y | N | 19 | Alive |
12 | 75 | IIIC | R0 | Y | N | 70 | Alive |
13 | 61 | IB | R0 | Y | NA | 19 | Censored |
14 | 39 | IB | R0 | Y | Y | 56 | Alive |
15 | 54 | IIIB | 0.1-1Â cm | Y | Y | 53 | Alive |
16 | 34 | IC | R0 | Y | Y | 30 | Alive |
17 | 60 | IIIC | R0 | Y | Y | 41 | Alive |
18 | 40 | IA | R0 | Y | Y | 20 | Alive |
19 | 40 | IA | R0 | Y | Y | 59 | Alive |
20 | 53 | IIIC | 0.1-1Â cm | Y | N | 30 | Died |
21 | 57 | IIIC | R0 | Y | Y | 22 | Alive |
22 | 43 | IIIC | 0.1-1Â cm | Y | Y | 45 | Alive |
23 | 35 | IIIC | R0 | Y | Y | 87 | Alive |
24 | 55 | IIIC | R0 | Y | Y | 50 | Alive |
25 | 69 | IV | 0.1-1Â cm | Y | Y | 27 | Died |
26 | 62 | IIIC | 0.1-1Â cm | Y | N | 52 | Died |